ezetimibe has been researched along with cardiovascular agents in 6 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies (cardiovascular agents) | Trials (cardiovascular agents) | Recent Studies (post-2010) (cardiovascular agents) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 17,645 | 1,480 | 6,891 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Malik, P | 1 |
| Ali, J; Ali, M; Bali, V | 1 |
| Lüscher, TF | 1 |
| Chang, R; Liu, SY; Zhao, LM | 1 |
6 other study(ies) available for ezetimibe and cardiovascular agents
| Article | Year |
|---|---|
Promises kept and broken: new pharmaceuticals.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Agents; Cardiovascular Diseases; Directories as Topic; Drug Evaluation; Drug Industry; Ezetimibe; Humans; Internet; Ischemic Preconditioning, Myocardial; Nicorandil; Ontario; Product Surveillance, Postmarketing; Pyridines; Thiazepines | 2002 |
Avoid the risks of mixed medications. How to minimize dangerous interactions with cardiovascular drugs.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Agents; Drug Interactions; Eplerenone; Ezetimibe; Fluorobenzenes; Humans; Polypharmacy; Pyrimidines; Rosuvastatin Calcium; Spironolactone; Sulfonamides | 2003 |
[Stable coronary heart disease--lessons from the COURAGE Study. With intensive drug therapy on the success track].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Azetidines; Cardiovascular Agents; Combined Modality Therapy; Coronary Disease; Coronary Stenosis; Death, Sudden, Cardiac; Ezetimibe; Humans; Kaplan-Meier Estimate; Life Style; Multicenter Studies as Topic; Myocardial Infarction; Outcome and Process Assessment, Health Care; Randomized Controlled Trials as Topic; Simvastatin | 2008 |
Nanocarrier for the enhanced bioavailability of a cardiovascular agent: in vitro, pharmacodynamic, pharmacokinetic and stability assessment.
Topics: Animals; Anticholesteremic Agents; Azetidines; Biological Availability; Cardiovascular Agents; Cholesterol; Drug Carriers; Drug Stability; Drug Storage; Emulsions; Ezetimibe; Hypercholesterolemia; Microscopy, Electron, Transmission; Nanostructures; Particle Size; Rats; Rats, Wistar; Solubility; Surface Properties | 2011 |
Risk assessement and its management: from SCORE to statins, ezetimibe to PCSK inhibitors.
Topics: Cardiovascular Agents; Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PCSK9 Inhibitors; Practice Guidelines as Topic; Risk Assessment | 2017 |
Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis.
Topics: Cardiovascular Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diuretics; Ezetimibe; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Meta-Analysis as Topic; Socioeconomic Factors; Sodium-Glucose Transporter 2 Inhibitors; Systematic Reviews as Topic | 2021 |